Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Basic studies suggest that statins as add-on therapy may benefit patients with COVID-19; however, real-world evidence of such a beneficial association is lacking.
Objective: We investigated differences in SARS-CoV-2 test positivity and clinical outcomes of COVID-19 (composite endpoint: admission to intensive care unit, invasive ventilation, or death) between statin users and nonusers.
Methods: Two independent population-based cohorts were analyzed, and we investigated the differences in SARS-CoV-2 test positivity and severe clinical outcomes of COVID-19, such as admission to the intensive care unit, invasive ventilation, or death, between statin users and nonusers. One group comprised an unmatched cohort of 214,207 patients who underwent SARS-CoV-2 testing from the Global Research Collaboration Project (GRCP)-COVID cohort, and the other group comprised an unmatched cohort of 74,866 patients who underwent SARS-CoV-2 testing from the National Health Insurance Service (NHIS)-COVID cohort.
Results: The GRCP-COVID cohort with propensity score matching had 29,701 statin users and 29,701 matched nonusers. The SARS-CoV-2 test positivity rate was not associated with statin use (statin users, 2.82% [837/29,701]; nonusers, 2.65% [787/29,701]; adjusted relative risk [aRR] 0.97; 95% CI 0.88-1.07). Among patients with confirmed COVID-19 in the GRCP-COVID cohort, 804 were statin users and 1573 were matched nonusers. Statin users were associated with a decreased likelihood of severe clinical outcomes (statin users, 3.98% [32/804]; nonusers, 5.40% [85/1573]; aRR 0.62; 95% CI 0.41-0.91) and length of hospital stay (statin users, 23.8 days; nonusers, 26.3 days; adjusted mean difference -2.87; 95% CI -5.68 to -0.93) than nonusers. The results of the NHIS-COVID cohort were similar to the primary results of the GRCP-COVID cohort.
Conclusions: Our findings indicate that prior statin use is related to a decreased risk of worsening clinical outcomes of COVID-19 and length of hospital stay but not to that of SARS-CoV-2 infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510150 | PMC |
| http://dx.doi.org/10.2196/29379 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India.
JRSM Cardiovasc Dis
September 2025
Division of Reproductive, Child Health and Nutrition, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Background: Statins are the most widely prescribed drugs for dyslipidemia and CAD. But evidence on their cognitive effects is conflicting. A unique genetic makeup and variable lipid patterns make South Asians more susceptible to statin adverse effects.
View Article and Find Full Text PDFBackground: Statin adherence impacts cardiovascular outcomes, yet disparities persist. Understanding sociodemographic factors and barriers is crucial for targeted interventions.
Objective: To investigate the relationship between sociodemographic factors and statin adherence across racial and ethnic groups.
Association between statin therapy and incident diabetes mellitus in patients with nephrotic syndrome: a retrospective cohort study.
BMC Nephrol
August 2025
Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430014, China.
Background: The use of statins and other lipid-lowering therapies for nephrotic syndrome (NS) patients with dyslipidemia remains controversial. This study aimed to evaluate the impact of long-term statin therapy on the risk of developing diabetes mellitus (DM) in patients with NS.
Methods: A retrospective cohort study was conducted from January 2018 to December 2024.
Real-World Experience from Türkiye: Genetic and Therapeutic Insights in Pediatric Heterozygous Familial Hypercholesterolemia.
J Clin Res Pediatr Endocrinol
August 2025
Ege University Faculty of Medicine, Department of Pediatrics, Division of Metabolism and Nutrition, İzmir, Turkey.
Objective: Familial hypercholesterolemia (FH) is an inherited metabolic disorder that increases cardiovascular risk from childhood. Despite its frequency, pediatric diagnosis and treatment remain inadequate, particularly in developing countries.
Methods: We retrospectively analysed 124 pediatric patients with genetically confirmed heterozygous FH (HeFH).
Guideline-directed medical therapy and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: analysis of two nationwide retrospective cohort studies.
BMJ Open
August 2025
Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Objectives: The purpose of this study was to verify whether guideline-directed medical therapy (GDMT, ie, the combined use of β-blocker, ACE inhibitor/angiotensin receptor blocker, dual antiplatelet drugs and statin) could improve in-hospital mortality in acute coronary syndrome (ACS) patients with advanced renal dysfunction (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m).
Design: Retrospective cohort study.